ProMetic Life Sciences (PFSCF) Stock Price, News & Analysis

Company Overview

ProMetic Life Sciences Inc. was a Canadian biopharmaceutical company focused on developing plasma-derived therapeutics and technologies for the purification of proteins. Its proprietary Mimetic Ligand technology was designed to selectively capture and purify proteins from human plasma and other biological materials, with potential applications in the manufacture of medicines.

The company’s development programs included plasminogen replacement therapy for patients with congenital plasminogen deficiency, as well as other plasma-derived products and treatments for immune, hematological, and metabolic conditions. ProMetic also pursued partnerships and commercial opportunities involving its purification technology and biologics manufacturing capabilities.

ProMetic served international pharmaceutical and biotechnology markets through research, development, manufacturing, and licensing activities. The company later changed its name to Liminal BioSciences Inc., reflecting a broader focus on plasma-derived therapeutics and drug development. Its operations and corporate structure subsequently underwent significant changes, so historical descriptions of ProMetic may not reflect the company’s later status.

Key Stats

• Today's Range: $5.47 to $5.47
• 50-Day Range: $5.47 to $5.47
• 52-Week Range: $5.47 to $352.00
• Volume: N/A
• Average Volume: 279 shs
• Market Capitalization: $127.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:PFSCF
• Previous Symbol: NASDAQ:PFSCF
• CIK: N/A
• Web: liminalbiosciences.com
• Phone: 1-450-781-0115
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$150.73 million
• Net Margins: -894.02%
• Pretax Margin: N/A
• Return on Equity: -3,350.55%
• Return on Assets: -67.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.95
• Quick Ratio: 0.71

Sales & Book Value

• Annual Sales: $36.55 million
• Price / Sales: 3.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($67.63) per share
• Price / Book: -0.08

Miscellaneous

• Outstanding Shares: 23,313,000
• Free Float: N/A
• Market Cap: $127.45 million
• Optionable: Not Optionable
• Beta: 2.46